TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.45M | 938.00K | 2.03M | 1.53M | 734.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.09M | 2.17M | 5.11M | 3.29M | 4.10M |
| Operating Income | -5.09M | -2.17M | -5.11M | -3.29M | -4.10M |
| Income Before Tax | -5.92M | -2.32M | -5.19M | -3.33M | -4.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.92M | -2.32M | -5.19M | -3.33M | -4.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.92M | -2.32M | -5.19M | -3.33M | -4.09M |
| EBIT | -5.09M | -2.17M | -5.11M | -3.29M | -4.10M |
| EBITDA | -5.08M | -2.15M | -5.08M | -3.26M | -4.07M |
| EPS Basic | -9.70 | -5.22 | -24.29 | -21.35 | -241.97 |
| Normalized Basic EPS | -6.06 | -3.26 | -15.18 | -13.34 | -151.23 |
| EPS Diluted | -9.70 | -5.22 | -24.29 | -21.35 | -241.97 |
| Normalized Diluted EPS | -6.06 | -3.26 | -15.18 | -13.34 | -151.23 |
| Average Basic Shares Outstanding | 610.00K | 445.00K | 213.70K | 155.80K | 16.90K |
| Average Diluted Shares Outstanding | 610.00K | 445.00K | 213.70K | 155.80K | 16.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |